Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

Share Price is delayed by 15 minutes
Get Live Data
222.00    -5.00 (-2.20%)
Bid:
222.00
Ask:
232.00
Spread: 10.00 (4.505%)
Market Cap: £117.21m
APTD Live PriceLast checked at - London Stock Exchange

Intraday Aptitude Share Chart

Interim Management Statement

13 May 2013 07:00

RNS Number : 4884E
Microgen PLC
13 May 2013
 



microgen

www.microgen.com

 

13 May 2013

 

INTERIM MANAGEMENT STATEMENT

 

 

Microgen plc ('Microgen' or 'Group') provides its Interim Management Statement covering the period from 1 January 2013 to the date of this announcement. Microgen released its final results for the year ending 31 December 2012 on 25 February 2013.

 

There have been no significant changes since 1 January 2013 in the financial position of Microgen and its balance sheet remains strong. The Group had net cash at 30 April 2013 of £32.3 million (31 December 2012 : £32.1 million) before payment of the dividend and special dividend totalling £6.1 million, scheduled for 28 May 2013.

 

The Board remains satisfied with the financial performance of the Group with benefit continuing to be received from its conservative operational approach and annual licencing model. The Financial Systems Division has commenced delivery of a significant 5Series project with a large global bank and continues to perform satisfactorily. The Microgen Aptitude Solutions Division ("MASD") has started implementation of a major new financial services project in North America based on both Microgen Aptitude and Accounting Hub. In addition, MASD has further strengthened its intellectual property portfolio with three new patents being granted by the US Patent Office since 1 January 2013 in respect of the Microgen Aptitude technology.

 

Strategic Review

 

The Microgen Group continues to be financially very robust with a strong balance sheet and consistent profitability/cash flow. Following payment of the dividend and special dividend, through the Board's pro-active shareholder realisation programme, Microgen will have returned to shareholders 100% of the market capitalisation as at 13 October 2008 via dividends, special dividends, tender offers and share buy-backs.

 

The Microgen Aptitude technology and related applications (e.g. Microgen Accounting Hub) continue to be affirmed as being market leading. Originally targeted at the financial services sector, which remains the core of the business, Microgen Aptitude has also established a strong reputation in the digital media sector and is now developing opportunities in both the telecom and healthcare sectors.

 

The Financial Systems Division operates in more established product categories with high recurring revenues. The core business which operates within the financial services sector has been stable for a number of years and continues to provide predictable cash flows. Furthermore, the investment in the development of the 5Series Trust & Fund administration product and an increasingly active wealth management market, have resulted in a number of new customer wins during the past year as well as upgrades from the previous 4Series product version.

 

Notwithstanding these strengths and the success of the shareholder realisation programme since October 2008, Microgen is constrained as a result of being a small, independent public company. As a provider of enterprise solutions in a risk-averse market environment, the size of the group can be an inhibitor given the very large enterprise software companies with which MASD typically competes. As a result, the Board has determined this to be an appropriate time to evaluate the Group's future strategy to maximise the potential of Microgen's market-leading technology and applications and has therefore decided to undertake a strategic review of the Group.

 

Given the financial strength of Microgen, continuing with the current strategy and structure remains a viable option. Nevertheless, the strategic review will be wide-ranging and may, or may not, result in the disposal of one or both of the operating divisions. Alternatively, the Board will also consider the merits of acquisition(s) to increase the scale of the Group, including acquisition(s) which may or may not provide operating synergies with the current operating divisions. Investec Bank Plc has been appointed to assist the Board in the strategic review.

 

The Board anticipates that this process will take several months. Further announcements will be made as appropriate.

 

 

 

 

 

 

 

Contacts

Martyn Ratcliffe, Chairman 020-7496-8100

David Sherriff, Chief Executive Officer

Philip Wood, Group Finance Director

 

James Melville-Ross, FTI Consulting 020-7831-3113

Lucy Delaney, FTI Consulting

 

Rowena Murray, Investec Bank Plc 020-7597 5970

Andrew Pinder, Investec Bank Plc

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSAMMATMBABBTJ
Date   Source Headline
24th Mar 201112:22 pmRNSAnnual Information Update
2nd Mar 201110:11 amRNSHolding(s) in Company
28th Feb 201110:15 amRNSTotal Voting Rights
25th Feb 201111:53 amRNSDirector/PDMR Shareholding
24th Feb 20117:00 amRNSFinal Results
16th Feb 20113:18 pmRNSNotice of Results
3rd Feb 20115:00 pmRNSHolding(s) in Company
3rd Feb 20114:58 pmRNSHolding(s) in Company
28th Jan 201112:59 pmRNSHolding(s) in Company
17th Jan 20114:18 pmRNSDirector Declaration
14th Jan 20114:18 pmRNSHolding(s) in Company
10th Jan 20117:00 amRNSPre-close Trading Update
7th Jan 201111:49 amRNSBlocklisting Return
7th Jan 201111:48 amRNSBlocklisting Return
4th Jan 201110:10 amRNSTotal Voting Rights
4th Nov 20107:00 amRNSDirector/PDMR Shareholding
3rd Nov 20103:40 pmRNSHolding(s) in Company
29th Oct 201010:00 amRNSTotal Voting Rights
26th Oct 20107:00 amRNSInterim Management Statement
26th Oct 20107:00 amRNSInterim Management Statement
30th Sep 20107:00 amRNSTotal Voting Rights
29th Sep 20108:05 amRNSDirector/PDMR Shareholding
27th Sep 20107:01 amRNSBlocklisting Interim Review
23rd Sep 201010:59 amRNSApplication for Blocklisting
15th Sep 20107:00 amRNSMicrogen Aptitude Modules Launch
9th Sep 20102:37 pmRNSHolding(s) in Company
6th Sep 201012:38 pmRNSHolding(s) in Company
2nd Sep 20104:32 pmRNSHolding(s) in Company
31st Aug 20101:19 pmRNSTotal Voting Rights
23rd Aug 20102:12 pmRNSDirector/PDMR Shareholding
23rd Aug 20107:00 amRNSResult of Tender Offer
19th Aug 201010:09 amRNSGM Announcement
11th Aug 201011:16 amRNSHolding(s) in Company
2nd Aug 20101:15 pmRNSPosting of Shareholder Circular
26th Jul 201012:49 pmRNSHolding(s) in Company
22nd Jul 20107:00 amRNSInterim Results
14th Jul 20103:30 pmRNSNotice of Results
1st Jul 201012:51 pmRNSBlocklisting Interim Review
1st Jul 201012:46 pmRNSBlocklisting Interim Review
24th Jun 20104:35 pmRNSDirector/PDMR Shareholding
3rd Jun 20104:38 pmRNSHolding(s) in Company
1st Jun 20102:14 pmRNSDirector Declaration
4th May 20109:57 amRNSTotal Voting Rights
27th Apr 201012:26 pmRNSDirector/PDMR Shareholding
23rd Apr 20102:41 pmRNSDirector/PDMR Shareholding
22nd Apr 20107:00 amRNSInterim Management Statement
16th Apr 20101:56 pmRNSDirector Declaration
22nd Mar 201010:03 amRNSAGM Statement
18th Mar 201011:33 amRNSAnnual Information Update
16th Mar 20105:36 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.